Side-by-side financials for APRE and JNJ. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APRE | JNJ |
|---|---|---|
| Market cap | - | $579.39 B |
| US-listed rank | - | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | -$12.60M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.6 |
| SEC filings | 425 | 984 |
Full pages: Aprea Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.